Publications by authors named "Willi Suter"

27Publications

The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.

Toxicol Sci 2014 Dec 21;142(2):427-35. Epub 2014 Sep 21.

*AstraZeneca R&D Mölndal, Pepparedsleden 1, 431 83, Mölndal, Sweden, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 ODP, UK, Novartis Pharma AG, PO Box, CH-4002, Basel, Switzerland, Amgen, Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, Janssen Research & Development, a division of Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium, Novartis Institutes for BioMedical Research, One Health Plaza, East Hanover, NJ 07936, Eli Lilly and company, Indianapolis, IN 46285, Association of the British Pharmaceutical Industry, 105 Victoria Street, London SW1E 6QT, UK, Pfizer Inc., Eastern Point Road, Groton, CT 06340 and Safety Pharmacology consultant, Sandwich, Kent, UK.

View Article and Find Full Text PDF
December 2014

Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation.

Heart Rhythm 2012 Oct 16;9(10):1706-15. Epub 2012 Jun 16.

Lankenau Institute for Medical Research and Main Line Health Heart Center, 100 Lancaster Ave., Wynnewood, PA 19096, USA.

View Article and Find Full Text PDF
October 2012

How do the top 12 pharmaceutical companies operate safety pharmacology?

J Pharmacol Toxicol Methods 2012 Sep 1;66(2):66-70. Epub 2012 Apr 1.

Global Safety Pharmacology, Global Safety Assessment, AstraZeneca R&D Alderley Park, Macclesfield, Cheshire, SK10 4TG, United Kingdom.

View Article and Find Full Text PDF
September 2012

Miniaturized flow cytometry-based in vitro primary human lymphocyte micronucleus assay-validation study.

Environ Mol Mutagen 2012 May 19;53(4):260-70. Epub 2012 Mar 19.

Genetic toxicology and Safety Pharmacology, Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
May 2012

In vitro primary human lymphocyte flow cytometry based micronucleus assay: simultaneous assessment of cell proliferation, apoptosis and MN frequency.

Mutagenesis 2011 Nov 26;26(6):763-70. Epub 2011 Jul 26.

Genetic Toxicology and Safety Pharmacology, Preclinical Safety, Novartis Institutes for Biomedical Research, Werk Klybeck, Klybeckstrasse 141, CH-4057 Basel, Switzerland.

View Article and Find Full Text PDF
November 2011

A flow cytometry based in vitro micronucleus assay in TK6 cells--validation using early stage pharmaceutical development compounds.

Environ Mol Mutagen 2011 Jun 20;52(5):363-72. Epub 2010 Oct 20.

Novartis Institutes for Biomedical Research, Preclinical Safety, Genetic Toxicology and Safety Pharmacology, Basel, Switzerland.

View Article and Find Full Text PDF
June 2011

Flow cytometry peripheral blood micronucleus test in vivo: determination of potential thresholds for aneuploidy induced by spindle poisons.

Environ Mol Mutagen 2010 May;51(4):278-84

Genetic Toxicology and Safety Pharmacology, Preclinical Safety, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
May 2010

Cytogenetic assessment of methylphenidate treatment in pediatric patients treated for attention deficit hyperactivity disorder.

Mutat Res 2009 Jun-Jul;677(1-2):53-8. Epub 2009 May 22.

Department of Biological Sciences, Wayne State University, 5047 Gullen Mall, Detroit, MI 48202-3917, United States.

View Article and Find Full Text PDF
September 2009

Repair of sparfloxacin-induced photochemical DNA damage in vivo.

J Invest Dermatol 2009 Mar 4;129(3):699-704. Epub 2008 Sep 4.

Novartis Pharma AG, Preclinical Safety, Genetic Toxicology and Safety Pharmacology, Basel, Switzerland.

View Article and Find Full Text PDF
March 2009

The photo comet assay--a fast screening assay for the determination of photogenotoxicity in vitro.

Mutat Res 2007 Aug 5;632(1-2):44-57. Epub 2007 May 5.

Genetic Toxicology and Safety Pharmacology, Exploratory Development, Novartis Pharma AG, Basel, Switzerland.

View Article and Find Full Text PDF
August 2007

Comparison of the peripheral blood micronucleus test using flow cytometry in rat and mouse exposed to aneugens after single-dose applications.

Mutagenesis 2007 Mar 6;22(2):129-34. Epub 2007 Feb 6.

Safety Profiling and Assessment, Exploratory Development, Novartis Pharma AG, MUT-2881.5.44, CH4002 Basel, Switzerland.

View Article and Find Full Text PDF
March 2007

In vivo micronucleus test with flow cytometry after acute and chronic exposures of rats to chemicals.

Mutat Res 2007 Jan 15;626(1-2):26-33. Epub 2006 Sep 15.

Safety Assessment and Profiling, Exploratory Development, Novartis Pharma AG, MUT-2881.5.44, CH4002 Basel, Switzerland.

View Article and Find Full Text PDF
January 2007

Methylphenidate is not clastogenic in cultured human lymphocytes and in the mouse bone-marrow micronucleus test.

Mutat Res 2006 Sep 7;607(2):153-9. Epub 2006 Jul 7.

Safety Assessment and Profiling, Exploratory Development, Novartis Pharma AG, MUT-2881.2.35, CH4002 Basel, Switzerland.

View Article and Find Full Text PDF
September 2006

Predictive value of in vitro safety studies.

Authors:
Willi Suter

Curr Opin Chem Biol 2006 Aug 3;10(4):362-6. Epub 2006 Jul 3.

Exploratory Development, Safety Profiling and Assessment, Novartis Pharma AG, CH 4002 Basel, Switzerland.

View Article and Find Full Text PDF
August 2006

Structure-activity considerations and in vitro approaches to assess the genotoxicity of 19 methane-, benzene- and toluenesulfonic acid esters.

Mutat Res 2005 Mar 21;581(1-2):23-34. Epub 2004 Dec 21.

Preclinical Safety Europe, Novartis Pharma AG, MUT-2881.2.29, CH 4002 Basel, Basel, Switzerland.

View Article and Find Full Text PDF
March 2005